DuPont de Nemours, Inc.: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Oct 30, 2020 and accepted by EDGAR at Oct 30, 2020, 09:09 ET.
Management's discussion and analysis
As filed, 77,188 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Effective August 31, 2017, pursuant to the merger of equals transactions contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("DWDP Merger Agreement"), The Dow Chemical Company ("Historical Dow") and E. I. du Pont de Nemours and Company ("Historical EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, Historical Dow and Historical EID became subsidiaries of DowDuPont (the "DWDP Merger"). Prior to the DWDP Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the DWDP Merger Agreement. Historical Dow was determined to be the accounting acquirer in the DWDP Merger.
DowDuPont completed a series of internal reorganizations and realignment steps in order to separate into three, independent, publicly traded companies - one for each of its agriculture, materials science and specialty products businesses. DowDuPont formed two wholly owned subsidiaries: Dow Inc. ("Dow", formerly known as Dow Holdings Inc.), to serve as a holding company for its materials science business, and Corteva, Inc. ("Corteva"), to serve as a holding company for its agriculture business.
Effective as of 5:00 p.m. on April 1, 2019, DowDuPont completed the separation of its materials science business into a separate and independent public company by way of a distribution of Dow through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock, par value $0.01 per share (the “Dow Common Stock”), to holders of the Company’s common stock, par value $0.01 per share (the “DowDuPont common stock”), as of the close of business on March 21, 2019 (the “Dow Distribution”).
Effective as of 12:01 a.m. on June 1, 2019, DuPont de Nemours, Inc. (formerly known as DowDuPont Inc.), completed the separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock, par value $0.01 per share (the “Corteva Common Stock”), to holders of the Company’s common stock, par value $0.01 per share, as of the close of business on May 24, 2019 (the “Corteva Distribution” and, together with the Dow Distribution, the “DWDP Distributions”).
Following the Corteva Distribution, the Company holds the specialty products business. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont" (the "Company"). Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD."
The results of operations of DuPont for the 2019 interim periods presented reflect the historical financial results of Dow and Corteva as discontinued operations, as applicable. The cash flows and comprehensive income related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable period. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva.
The statements of operations and pro forma statements of operations included in this report and as discussed below include costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with Financial Accounting Standards Codification 205, "Presentation of Financial Statements" ("ASC 205") and thus are reflected in the Company's results of continuing operations. A significant portion of these costs relate to Historical Dow and consist of leveraged services provided through service centers, as well as other corporate overhead costs related to information technology, finance, manufacturing, research & development, sales & marketing, supply chain, human resources, sourcing & logistics, legal and communications, public affairs & government affairs functions. These costs are no longer incurred by the Company following the DWDP Distributions.
On December 15, 2019, the Company entered into definitive agreements to separate and combine the Nutrition & Biosciences business segment (the "N&B Business") with International Flavors & Fragrances Inc. ("IFF") in a tax-efficient Reverse Morris Trust transaction, (the "Intended N&B Transaction"). The transaction is expected to close in the first quarter of 2021, subject to approval by IFF shareholders and other customary closing conditions, including regulatory approvals and receipt by DuPont of an opinion of tax counsel. The financial results of the N&B Business are included in continuing operations for the periods presented.
RECENT DEVELOPMENTS
COVID-19
The novel coronavirus (“COVID-19”) pandemic has resulted in significant economic disruption and continues to adversely impact the broader global economy, including certain of the Company’s customers and suppliers. Given the dynamic nature of this situation, the Company cannot reasonably estimate the impacts of COVID-19 on its financial condition, results of operations or cash flows into the foreseeable future. The ultimate extent of the effects of the COVID-19 pandemic on the Company is highly uncertain and will depend on future developments, and such effects could exist for an extended period of time even after the pandemic subsides.
During the third quarter of 2020, the Company benefited from strong demand in certain key end-markets, principally electronics, water filtration, health & wellness and personal protection. In addition, third quarter 2020 results reflect notable improvements in automotive markets, along with residential construction, compared to second quarter of 2020. Although management currently expects continued improvement from certain markets in the fourth quarter of 2020, the COVID-19 pandemic is expected to continue to adversely impact demand in aerospace, commercial construction, oil & gas, and select industrial end-markets. In response to this uncertainty, the Company has delayed certain capital investments in select sectors.
Sale of TCS/HSC Disposal Group
In the third quarter of 2020, the Company completed the sale of its trichlorosilane business (“TCS Business”) along with its equity ownership interest in DC HSC Holdings LLC and Hemlock Semiconductor L.L.C. (the "HSC Group,” and together with the TCS Business, the “TCS/HSC Disposal Group” and the sale of the TCS/HSC Disposal Group, the “TCS/HSC Disposal”) to the HSC Group, both of which were part of the Non-Core segment. In connection with the TCS/HSC Disposal, the Company received $550 million in cash at closing, subject to certain claw-back provisions, and will receive an additional $175 million in equal installments over the course of the next three years associated with the settlement of an existing supply agreement dispute with the HSC Group. The TCS/HSC Disposal resulted in a net pre-tax benefit of $393 million ($232 million net of tax), including the settlement of the supply agreement dispute and after allocation of goodwill to the TCS Business. The net pre-tax benefit is recorded in “Sundry income (expense) – net” in the Company’s interim Consolidated Statements of Operations. Refer to Note 3 of the interim Consolidated Financial Statements.
Non-Core Impairments
Multiple triggering events occurred in the third quarter of 2020 requiring the Company to perform impairment analyses associated with its Non-Core segment. As a result of the analyses performed, the Company recognized aggregate pre-tax, non-cash goodwill impairment charges of $183 million recorded within "Goodwill impairment charges" and aggregate pre-tax, non-cash asset impairment charges of $370 million recorded within “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operations. Refer to Notes 3, 5, and 11 of the interim Consolidated Financial Statements.
Nutrition & Biosciences Notes Offering
On September 16, 2020, Nutrition & Biosciences, Inc. (presently a wholly owned subsidiary of DuPont) (“N&B Inc.”) completed an offering of $6.25 billion of senior unsecured notes (the “N&B Notes Offering”). The net proceeds of approximately $6.2 billion from the N&B Notes Offering were deposited into an escrow account. Prior to the intended merger of DuPont's Nutrition & Biosciences business with IFF, N&B Inc. will make a special cash payment of $7.3 billion, (the “Special Cash Payment”), subject to adjustment, to DuPont, which N&B Inc. will fund with the net proceeds from the N&B Notes Offering together with borrowings under N&B Inc.’s existing Term Loan facilities. Refer to Notes 6 and 12 of the interim Consolidated Financial Statements.
Dividends
On June 25, 2020, the Company announced that its Board of Directors declared a third quarter dividend of $0.30 per share paid on September 15, 2020, to shareholders of record on July 31, 2020.
On October 14, 2020, the Company announced that its Board of Directors declared a fourth quarter dividend of $0.30 per share payable on December 15, 2020, to shareholders of record on November 30, 2020.
SELECTED FINANCIAL DATA
In millions, except per share amounts
| Three Months Ended September 30, 2020 | 2019 | Nine Months Ended September 30, 2020 | 2019 | |
|---|---|---|---|---|
| Net sales | $5,096 | $5,426 | $15,145 | $16,308 |
| Cost of sales | $3,392 | $3,531 | $10,001 | $10,648 |
| Percent of net sales | 66.6% | 65.1% | 66.0% | 65.3% |
| Research and development expenses | $199 | $225 | $644 | $724 |
| Percent of net sales | 3.9% | 4.1% | 4.3% | 4.4% |
| Selling, general and administrative expenses | $524 | $645 | $1,698 | $2,013 |
| Percent of net sales | 10.3% | 11.9% | 11.2% | 12.3% |
| Effective tax rate - continuing operations | 460.0% | 17.3% | (3.3)% | (21.4)% |
| Net (loss) earnings available for DuPont common stockholders | $(79) | $372 | $(3,173) | $322 |
| (Loss) earnings per common share – basic | $(0.11) | $0.50 | $(4.31) | $0.43 |
| (Loss) earnings per common share – diluted | $(0.11) | $0.50 | $(4.31) | $0.43 |
RESULTS OF OPERATIONS
In millions
| Summary of Sales Results | Three Months Ended September 30, 2020 | 2019 | Nine Months Ended September 30, 2020 | 2019 |
|---|---|---|---|---|
| Net sales | $5,096 | $5,426 | $15,145 | $16,308 |
The following table summarizes sales variances by segment and geographic region from the prior year:
Sales Variances by Segment and Geographic Region
| Percentage change from prior year | Three Months Ended September 30, 2020 Local Price & Product Mix | Currency | Volume | Portfolio & Other | Total | Nine Months Ended September 30, 2020 Local Price & Product Mix | Currency | Volume | Portfolio & Other | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Electronics & Imaging | (1)% | —% | 9% | (1)% | 7% | (1)% | —% | 8% | —% | 7% |
| Nutrition & Biosciences | — | — | (4) | — | (4) | 1 | (1) | (1) | — | (1) |
| Transportation & Industrial | (5) | — | (9) | — | (14) | (5) | — | (15) | — | (20) |
| Safety & Construction | 1 | — | (10) | 3 | (6) | 2 | (1) | (8) | 2 | (5) |
| Non-Core | 5 | — | (18) | (10) | (23) | 3 | (1) | (17) | (9) | (24) |
| Total | —% | —% | (6)% | —% | (6)% | —% | (1)% | (6)% | —% | (7)% |
| U.S. & Canada | (1)% | —% | (9)% | (1)% | (11)% | (1)% | —% | (9)% | —% | (10)% |
| EMEA 1 | (1) | 2 | (14) | — | (13) | — | (1) | (12) | — | (13) |
| Asia Pacific | (1) | — | 4 | — | 3 | (1) | (1) | 2 | — | — |
| Latin America | 5 | (6) | (8) | (1) | (10) | 3 | (5) | (11) | (1) | (14) |
| Total | —% | —% | (6)% | —% | (6)% | —% | (1)% | (6)% | —% | (7)% |
1. Europe, Middle East and Africa.
The Company reported net sales for the three months ended September 30, 2020 of $5.1 billion, down 6 percent from $5.4 billion for the three months ended September 30, 2019, due to a 6 percent decrease in volume. Local price and product mix, currency, and portfolio remained flat. Volume declined across all geographic regions with the exception of Asia Pacific where it increased 4 percent. Volume declined across all segments with the exception of Electronics & Imaging (up 9 percent). The most notable volume decreases were in Non-Core (down 18 percent), Safety & Construction (down 10 percent) and Transportation & Industrial (down 9 percent). Currency was flat compared with the same period last year in all segments. Portfolio and other changes were flat overall while Non-Core saw a decrease of 10 percent. Local price was flat compared with the same period last year. Local price increased in Latin America (up 5 percent) and in Non-Core (up 5 percent) and Safety & Construction (up 1 percent).
Net sales for the nine months ended September 30, 2020 were $15.1 billion, down 7 percent from $16.3 billion for the nine months ended September 30, 2019, due to a 6 percent decrease in volume and a 1 percent unfavorable currency impact. Local price and product mix and portfolio actions remained flat. Volume declined across all geographic regions with the exception of Asia Pacific where it increased 2 percent. Volume declined across all segments with the exception of Electronics & Imaging (up 8 percent). The most notable volume decreases were in Non-Core (down 17 percent), Transportation & Industrial (down 15 percent) and Safety-Construction (down 8 percent). Currency was down 1 percent compared with the same period last year, driven primarily by Latin American currencies (down 5 percent) and EMEA and Asia Pacific currencies (down 1 percent each). Portfolio and other changes were flat overall while Non-Core saw a negative impact on sales from portfolio changes (down 9 percent). Local price and product mix was flat compared with the same period last year. Local price increased in Latin America (up 3 percent) and in all segments except Transportation & Industrial (down 5 percent) and Electronics & Imaging (down 1 percent).
Cost of Sales
Cost of sales was $3.4 billion for the three months ended September 30, 2020, down from $3.5 billion for the three months ended September 30, 2019 primarily due to lower sales volume and cost synergies offset by approximately $60 million of charges associated with temporarily idling several manufacturing plants to align supply with demand, mainly in the Transportation & Industrial and Safety & Construction segments.
Cost of sales as a percentage of net sales for the three months ended September 30, 2020 was 67 percent compared with 65 percent for the three months ended September 30, 2019, driven mainly by the charges associated with temporary idling several manufacturing plans referenced above.
For the nine months ended September 30, 2020, cost of sales was $10.0 billion, down from $10.6 billion for the nine months ended September 30, 2019. Cost of sales decreased for the nine months ended September 30, 2020 primarily due to lower sales volume, cost synergies, currency impacts, and lower costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the DWDP Distributions, offset by approximately $220 million of charges associated with temporarily idling several manufacturing plants to align supply with demand due to COVID-19, driven primarily by the Transportation & Industrial segment.
Cost of sales as a percentage of net sales for the nine months ended September 30, 2020 was 66 percent compared with 65 percent for the nine months ended September 30, 2019.
Research and Development Expenses ("R&D")
R&D expenses totaled $199 million in the third quarter of 2020, down from $225 million in the third quarter of 2019. R&D as a percentage of net sales was 4 percent for the three months ended September 30, 2020 and 2019.
For the first nine months of 2020, R&D expenses totaled $644 million, down from $724 million in the first nine months of 2019. R&D as a percentage of net sales was 4 percent for the nine months ended September 30, 2020 and 2019.
Selling, General and Administrative Expenses ("SG&A")
SG&A expenses were $524 million in the third quarter of 2020, down from $645 million in the third quarter of 2019 primarily due to productivity actions and reduced spending. SG&A as a percentage of net sales was 10 percent and 12 percent for the three months ended September 30, 2020 and 2019, respectively.
For the first nine months of 2020, SG&A expenses totaled $1,698 million, down from $2,013 million in the first nine months of 2019. SG&A as a percentage of net sales was 11 percent and 12 percent for the nine months ended September 30, 2020 and 2019, respectively.
The decrease for the nine months ended September 30, 2020 compared with the same period of the prior year was primarily due to productivity actions, reduced spending and the absence of SG&A costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205 and therefore remained as costs of continuing operations for periods prior to the DWDP Distributions.
Amortization of Intangibles
Amortization of intangibles was $530 million in the third quarter of 2020, up from $247 million in the third quarter of 2019. In the first nine months of 2020, amortization of intangibles was $1,591 million, up from $755 million in the same period last year. The increase was primarily due to the amortization of the Nutrition and Biosciences tradenames that were reclassified to definite-lived intangibles in the fourth quarter of 2019 in connection with the Intended N&B Transaction.
Restructuring and Asset Related Charges - Net
Restructuring and asset related charges - net were $384 million in the third quarter of 2020, up from $82 million in the third quarter of 2019. The activity in the third quarter of 2020 included asset impairment charges in the Non-Core segment of $318 million related to long-lived assets and $52 million related to indefinite-lived intangible assets, and a $14 million charge related to the 2020 Restructuring Program. The charges in the third quarter of 2019 included a $69 million charge related to the 2019 Restructuring Program and a $13 million charge related to the DowDuPont Cost Synergy Program.
In the first nine months of 2020, restructuring and asset related charges - net were $807 million, up from $290 million in the same period last year. The activity for the nine months of 2020 included asset impairment charges in the Non-Core segment of $588 million related to long-lived assets and $52 million related to indefinite-lived intangible assets, a $21 million impairment charge related to indefinite-lived intangible assets in the Transportation & Industrial segment, a $140 million charge related to the 2020 Restructuring Program, a $2 million charge related to the 2019 Restructuring Program and a $4 million charge related to the DowDuPont Cost Synergy Program. The charges in the same period of 2019 included a charge of $122 million related to the 2019 Restructuring Program, a $105 million charge related to the DowDuPont Cost Synergy Program, and $63 million impairment charge related to an equity method investment.
See Note 5 to the interim Consolidated Financial Statements for additional information.
Goodwill Impairment Charges
Goodwill impairment charges were $183 million in the third quarter of 2020. There were no goodwill related impairments in the third quarter of 2019. Goodwill impairment charges were $3,214 million in the nine months ended September 30, 2020, up from $1,175 million in the same period last year. The third quarter of 2020 goodwill impairment charges relate to the Non-Core segment. In the first nine months of 2020, goodwill impairment charges relate to the Transportation & Industrial and Non-Core segments. Goodwill impairment charges for the first nine months of 2019 relate to the Nutrition & Biosciences and Non-Core segments. See Note 11 to the interim Consolidated Financial Statements for additional information.
Integration and Separation Costs
Integration and separation costs, which primarily reflect costs related to the Intended N&B Transaction beginning in the fourth quarter of 2019, the post-DWDP Merger integration, and activities related to the DWDP Distributions, were $127 million in the third quarter of 2020, down from $191 million in the third quarter of 2019. In the first nine months of 2020, integration and separation costs were $469 million, down from $1,149 million in the same period last year. The decline was primarily related to the timing of the DWDP Distributions.
Equity in Earnings of Nonconsolidated Affiliates
The Company's share of the earnings of nonconsolidated affiliates was $30 million in the third quarter of 2020, down from $43 million in the third quarter of 2019 primarily due to lower HSC Group equity earnings coupled with the sale of the Company's equity interest in the HSC Group in the third quarter of 2020. In the first nine months of 2020, the Company's share of the earnings of nonconsolidated affiliates was $172 million, up from $132 million in the first nine months of 2019. The increase is primarily due to higher HSC Group equity earnings in the first half of 2020, mainly driven by customer settlements in the second quarter of 2020.
Sundry Income (Expense) - Net
Sundry income (expense) - net includes a variety of income and expense items such as foreign currency exchange gains or losses, interest income, dividends from investments, gains and losses on sales of investments and assets, non-operating pension and other post-employment benefit plan credits or costs, and certain litigation matters. Sundry income (expense) - net in the third quarter of 2020 was income of $430 million compared with income of $79 million in the third quarter of 2019.
The third quarter of 2020 included a net pre-tax benefit of $393 million related to the TCS/HSC Disposal in the Non-Core segment, which includes the settlement of a supply agreement dispute. The third quarter of 2019 included benefits related to sales of assets of $64 million and income related to non-operating pension and other post-employment benefit credits of $21 million, partially offset by foreign currency exchange losses of $23 million.
In the first nine months of 2020, sundry income (expense) - net was income of $627 million compared with income of $144 million in the first nine months of 2019. The first nine months of 2020 included a net pre-tax net benefit of $393 million associated with the TCS/HSC Disposal as discussed above, a gain of $197 million related to the sale of the Compound Semiconductor Solutions business unit in the Electronics & Imaging segment, and income related to non-operating pension and other post-employment benefit credits of $24 million, partially offset by foreign currency exchange losses of $41 million. The first nine months of 2019 included benefits related to sales of assets of $127 million, income related to non-operating pension and other post-employment benefit plans of $60 million and interest income of $50 million, partially offset by foreign currency exchange losses of $101 million and a $48 million charge reflecting a reduction in gross proceeds from lower withholding taxes related to a prior year legal settlement.
Interest Expense
Interest expense was $197 million in the third quarter of 2020, up from $177 million in the third quarter of 2019. The increase primarily relates to financing costs associated with the Intended N&B transaction.
In the first nine months of 2020, interest expense was $573 million, up from $493 million in the same period last year. The increase primarily relates to financing costs associated with the Intended N&B Transaction and the May Debt Offering.
Provision for Income Taxes on Continuing Operations
The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attribute. The effective tax rate on continuing operations for the third quarter of 2020 was 460.0 percent, compared with an effective tax rate of 17.3 percent for the third quarter of 2019. The effective tax rate for the third quarter of 2020 was principally the result of a non-tax-deductible goodwill impairment charge and a non-tax-deductible goodwill allocation in connection with the TCS/HSC Disposal impacting the Non-Core segment in the third quarter. The effective tax rate for the third quarter of 2019 was favorably impacted by, among other items, tax benefits related to the adjustment of certain unrecognized benefits for positions taken on items from a prior year.
For the first nine months of 2020, the effective tax rate on continuing operations was (3.3) percent, compared with (21.4) percent for the first nine months of 2019. The effective tax rate for the first nine months of 2020 was principally the result of a non-tax-deductible goodwill impairment charge impacting the Non-Core segment in the first and third quarter and a non-tax-deductible goodwill impairment charge impacting the Transportation and Industrial segment in the second quarter, coupled with an allocation of non-tax-deductible goodwill related to the TCS/HSC Disposal. The tax rate for the first nine months of 2019 was principally the result of non-tax-deductible goodwill impairment charges impacting the Nutrition & Biosciences and Non-Core segments. See Note 11 to the interim Consolidated Financial Statements for additional information on the goodwill impairment charges.
Income from Discontinued Operations, Net of Tax
In the third quarter of 2020 and for the first nine months of 2020, the Company did not have activity from discontinued operations. In the third quarter of 2019 and for the nine months of 2019, income from discontinued operation, net of tax was $5 million and $1,217 million, respectively. The decrease period over period is attributable to the timing of the DWDP Distributions. Refer to Note 3 to the interim Consolidated Financial Statements for additional information.
Net Income Attributable to Noncontrolling Interests
Net income attributable to noncontrolling interests was $7 million in the third quarter of 2020, up from $5 million in the third quarter of 2019. For the first nine months of 2020, net income attributable to noncontrolling interests was $20 million, down from $90 million for the same period last year due to the timing of the DWDP Distributions.
SUPPLEMENTAL UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
The following supplemental unaudited pro forma financial information (the “unaudited pro forma financial statements”) is derived from DuPont’s Consolidated Financial Statements, adjusted to give effect to certain events directly attributable to the DWDP Distributions. In contemplation of the DWDP Distributions and to achieve the respective credit profiles of each of the current companies, in the fourth quarter of 2018, DowDuPont borrowed $12.7 billion under the 2018 Senior Notes and entered the Term Loan Facilities with an aggregate principal amount of $3.0 billion. Additionally, DuPont issued approximately $1.4 billion in commercial paper in May 2019 in anticipation of the Corteva Distribution (the “Funding CP Issuance” together with the 2018 Senior Notes and the Term Loan Facilities, the "Financings"). The unaudited pro forma financial statements for the nine months ended September 30, 2019 were prepared in accordance with Article 11 of Regulation S-X. The historical consolidated financial information has been adjusted to give effect to pro forma events that are (1) directly attributable to the DWDP Distributions and the Financings (collectively the "Transactions"), (2) factually supportable and (3) with respect to the statements of operations, expected to have a continuing impact on the results. The unaudited pro forma statements of operations for the nine months ended September 30, 2019 give effect to the pro forma events as if they had been consummated on January 1, 2018. There were no pro forma adjustments for the three and nine months ended September 30, 2020 and for the three months ended September 30, 2019.
Restructuring or integration activities or other costs following the DWDP Distributions that may be incurred to achieve cost or growth synergies of DuPont are not reflected. The unaudited pro forma income statement provides shareholders with summary financial information and historical data that is on a basis consistent with how DuPont reports current financial information.
The unaudited pro forma financial statements are presented for informational purposes only, and do not purport to represent what DuPont's results of operations or financial position would have been had the Transactions occurred on the dates indicated, nor do they purport to project the results of operations or financial position for any future period or as of any future date.
Unaudited Pro Forma Combined Statements of Operations
In millions, except per share amounts
| 2019 | Nine Months Ended September 30, DuPont 1 | Pro Forma Adjustments2 | Pro Forma |
|---|---|---|---|
| Net sales | $16,308 | $— | $16,308 |
| Cost of sales | 10,648 | 22 | 10,670 |
| Research and development expenses | 724 | — | 724 |
| Selling, general and administrative expenses | 2,013 | — | 2,013 |
| Amortization of intangibles | 755 | — | 755 |
| Restructuring and asset related charges - net | 290 | — | 290 |
| Goodwill impairment charges | 1,175 | — | 1,175 |
| Integration and separation costs | 1,149 | (173) | 976 |
| Equity in earnings of nonconsolidated affiliates | 132 | — | 132 |
| Sundry income (expense) - net | 144 | — | 144 |
| Interest expense | 493 | 29 | 522 |
| Loss from continuing operations before income taxes | (663) | 122 | (541) |
| Provision for income taxes on continuing operations | 142 | 30 | 172 |
| Loss from continuing operations, net of tax | (805) | 92 | (713) |
| Net income attributable to noncontrolling interests of continuing operations | 18 | — | 18 |
| Net loss from continuing operations attributable to DuPont | $(823) | $92 | $(731) |
| Per common share data: | |||
| Loss per common share from continuing operations - basic | $(1.10) | $(0.98) | |
| Loss per common share from continuing operations - diluted | $(1.10) | $(0.98) | |
| Weighted-average common shares outstanding - basic | 748.2 | 748.2 | |
| Weighted-average common shares outstanding - diluted | 748.2 | 748.2 |
1. See the historical U.S. GAAP Consolidated Statements of Operations.
2. Certain pro forma adjustments were made to illustrate the estimated effects of the Transactions, assuming that the Transactions had occurred on January 1, 2018. The adjustments include the impact to "Cost of sales" of different pricing than historical intercompany and intracompany practices related to various supply agreements entered into with the Dow Distribution, adjustments to "Integration and separation costs" to eliminate one-time transaction costs directly attributable to the DWDP Distributions, and adjustments to "Interest expense" to reflect the impact of the Financings.
SEGMENT RESULTS
In the first quarter of 2020, in preparation for the Intended N&B Transaction, DuPont changed its management and reporting structure to realign costs associated with its polysaccharides pre-commercial activities from the Non-Core segment to the N&B segment. The reporting changes have been retrospectively reflected in the following discussion of segment results for all periods presented. Refer to Note 21 to the interim Consolidated Financial Statements for additional information.
Prior to April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is pro forma Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assessed performance and allocated resources. The Company defines pro forma Operating EBITDA as pro forma earnings (i.e., pro forma “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / other post-employment benefits (“OPEB”) / charges, and foreign exchange gains / losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and adjusted for significant items. Effective April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's CODM assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, adjusted for significant items. Reconciliations of these measures can be found in Note 21 to the interim Consolidated Financial Statements. Prior year data has been updated to conform with the current year presentation.
Pro forma adjustments used in the calculation of pro forma Operating EBITDA were determined in accordance with Article 11 of Regulation S-X and were derived from DuPont's historical Consolidated Financial Statements and accompanying notes, adjusted to give effect to the DWDP Distributions as if they had been consummated on January 1, 2018. The pro forma adjustments impacting pro forma Operating EBITDA reflect the impact of various supply agreements ("supply agreements") entered into in connection with the Dow Distribution and are outlined in the preceding section, Supplemental Unaudited Pro Forma Combined Financial Information, as adjustments to "Cost of sales." The impact of these supply agreements is reflected in pro forma Operating EBITDA for the periods noted above as it is included in the measure of profit/loss reviewed by the CODM in order to show meaningful comparability among periods while assessing performance and making resource allocation decisions. There were no pro forma adjustments for the three and nine months ended September 30, 2020 and for the three months ended September 30, 2019.
ELECTRONICS & IMAGING
The Electronics & Imaging segment is a leading global supplier of differentiated materials and systems for a broad range of consumer electronics including mobile devices, television monitors, personal computers and electronics used in a variety of industries. The segment is a leading provider of materials and solutions for the fabrication of semiconductors and integrated circuits, and provides innovative metallization processes for metal finishing, decorative, and industrial applications as well as films and laminate materials for a broad range of uses in printed circuit board and other electronic industry applications. Electronics & Imaging is a leading provider of platemaking systems and photopolymer plates for the packaging graphics industry and digital printing inks for a variety of applications in the textile, commercial printing, and home-office markets. In addition, the segment provides cutting-edge materials for the manufacturing of rigid and flexible displays for organic light emitting diode ("OLED"), and other display applications.
In millions
| Electronics & Imaging | Three Months Ended September 30, 2020 | September 30, 2019 | Nine Months Ended September 30, 2020 | September 30, 2019 |
|---|---|---|---|---|
| Net sales | $1,004 | $934 | $2,793 | $2,617 |
| Operating EBITDA 1 | $357 | $320 | $887 | $854 |
| Equity earnings | $8 | $10 | $27 | $18 |
1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis.
| Electronics & Imaging Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended September 30, 2020 | Nine Months Ended September 30, 2020 |
|---|---|---|
| Local price & product mix | (1)% | (1)% |
| Currency | — | — |
| Volume | 9 | 8 |
| Portfolio & other | (1) | — |
| Total | 7% | 7% |
Electronics & Imaging net sales were $1,004 million for the three months ended September 30, 2020, up 7 percent from $934 million for the three months ended September 30, 2019. Net sales increased due to a 9 percent increase in volume partially offset by a 1 percent local price decline and a 1 percent decrease from prior portfolio actions. Volume growth was driven by Semiconductor Technologies with continued strength in the logic and foundry segment. Volume growth within Interconnect Solutions was driven by increased material content in next-generation smartphones. Within Image Solutions, volume growth in OLED materials for displays offset weakness in flexographic plates and textile inks.
Operating EBITDA was $357 million for the three months ended September 30, 2020, up 12 percent compared with $320 million for the three months ended September 30, 2019 due to volume gains and cost productivity actions. The three months ended September 30, 2020 and 2019 include income of $30 million and $34 million, respectively, related to an asset sale from 2019.
Electronics & Imaging net sales were $2,793 million for the nine months ended September 30, 2020, up 7 percent from $2,617 million for the nine months ended September 30, 2019. Net sales increased due to an 8 percent volume growth offset by a 1 percent decline in local price. Volume growth was driven by demand in Semiconductor Technologies in the logic and foundry segment, higher material content in smartphones and increased demand for OLED materials.
Operating EBITDA was $887 million for the nine months ended September 30, 2020, down 4 percent compared with pro forma Operating EBITDA of $854 million for the nine months ended September 30, 2019. Favorable impacts from volume gains and cost productivity actions were offset by higher logistics costs and $55 million decrease in income compared to prior year related to a 2019 asset sale.
NUTRITION & BIOSCIENCES
The Nutrition & Biosciences segment is an innovation-driven and customer-focused segment that provides solutions for the global food and beverage, dietary supplements, home and personal care, energy, animal nutrition and pharma markets. The segment is one of the world's largest producers of specialty ingredients, developing and manufacturing solutions for the global food and beverage, dietary supplements, enzymes and pharmaceutical excipient markets. Additionally, the segment is an industry pioneer and innovator that works with customers to improve the performance, productivity and sustainability of their products and processes, through differentiated technology in ingredients applications, fermentation, biotechnology, chemistry and manufacturing process excellence.
In millions
| Nutrition & Biosciences | Three Months Ended September 30, 2020 | September 30, 2019 | Nine Months Ended September 30, 2020 | September 30, 2019 |
|---|---|---|---|---|
| Net sales | $1,467 | $1,525 | $4,557 | $4,618 |
| Operating EBITDA 1 | $379 | $354 | $1,182 | $1,089 |
| Equity earnings | $1 | $— | $2 | $— |
1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis.
| Nutrition & Biosciences Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended September 30, 2020 | Nine Months Ended September 30, 2020 |
|---|---|---|
| Local price & product mix | —% | 1% |
| Currency | — | (1) |
| Volume | (4) | (1) |
| Portfolio & other | — | — |
| Total | (4)% | (1)% |
Nutrition & Biosciences net sales were $1,467 million for the three months ended September 30, 2020, down 4 percent from $1,525 million for the three months ended September 30, 2019 due to a 4 percent decrease in volume. Food & Beverage volumes declined due to continued weak demand in food service and in sweeteners. Health & Biosciences volume gains in probiotics and strong demand in home & personal care were more than offset by declined demand in biorefinery and microbial control. Pharma Solutions sales were relatively flat compared to the prior period.
Operating EBITDA was $379 million for the three months ended September 30, 2020, up 7 percent compared with $354 million for the three months ended September 30, 2019 due to cost productivity actions and favorable product mix more than offsetting the lower volumes.
Nutrition & Biosciences net sales were $4,557 million for the nine months ended September 30, 2020, down 1 percent compared with $4,618 million for the nine months ended September 30, 2019. A 1 percent increase in local price was offset by a 1 percent decrease in volume and a 1 percent unfavorable currency impact. Food & Beverage volume declined due to decreased demand in food service and sweeteners applications, partially offset by higher demand for plant-based meat. Health & Biosciences volume gains were driven by probiotics along with strong demand in home & personal care and animal nutrition, offset by declined demand in biorefinery and microbial control. Pharma Solutions volume gains were driven by increased demand in key products.
Operating EBITDA was $1,182 million for the nine months ended September 30, 2020, up 9 percent compared with pro forma Operating EBITDA of $1,089 million for the nine months ended September 30, 2019 due to a cost productivity actions, favorable product mix led by Health & Biosciences, and pricing gains.
TRANSPORTATION & INDUSTRIAL
The Transportation & Industrial segment provides high-performance engineering resins, adhesives, silicones, lubricants and parts to engineers and designers in the transportation, electronics, healthcare, industrial and consumer end-markets to enable systems solutions for demanding applications and environments. The segment delivers a broad range of polymer-based high-performance materials in its product portfolio, including elastomers and thermoplastic and thermoset engineering polymers which are used by customers to fabricate components for mechanical, chemical and electrical systems. In addition, the segment produces innovative engineering polymer solutions, high performance parts, specialty silicones and differentiated adhesive technologies to meet customer specifications in automotive, aerospace, electronics, industrial, healthcare and consumer markets. Transportation & Industrial is a global leader of advanced materials that provides technologies that differentiate customers’ products with improved performance characteristics enabling the transition to hybrid-electric-connected vehicles, high speed high frequency connectivity and smart healthcare.
In millions
| Transportation & Industrial | Three Months Ended September 30, 2020 | September 30, 2019 | Nine Months Ended September 30, 2020 | September 30, 2019 |
|---|---|---|---|---|
| Net sales | $1,045 | $1,209 | $3,021 | $3,795 |
| Operating EBITDA 1 | $242 | $306 | $599 | $1,036 |
| Equity earnings | $1 | $1 | $3 | $3 |
1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis.
| Transportation & Industrial Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended September 30, 2020 | Nine Months Ended September 30, 2020 |
|---|---|---|
| Local price & product mix | (5)% | (5)% |
| Currency | — | — |
| Volume | (9) | (15) |
| Portfolio & other | — | — |
| Total | (14)% | (20)% |
Transportation & Industrial net sales were $1,045 million for the three months ended September 30, 2020, down from $1,209 million for the three months ended September 30, 2019. The change in net sales was due to a 9 percent decrease in volume and a 5 percent decrease in local price. While volume improved notably from second quarter of 2020, volume declines compared to prior year due to the impact of the COVID-19 pandemic on the automotive industry and the other key industrial end markets more than offset strong demand for KALREZ® within Healthcare & Specialty in the semiconductor market.
Operating EBITDA was $242 million for the three months ended September 30, 2020, down 21 percent compared with $306 million for the three months ended September 30, 2019. Cost productivity actions were more than offset by volume declines and the impact of temporarily idling manufacturing plants to align supply with demand due to the COVID-19 pandemic, along with lower price.
Transportation & Industrial net sales were $3,021 million for the nine months ended September 30, 2020, down from $3,795 million for the nine months ended September 30, 2019 due to a 15 percent decrease in volume and a 5 percent decrease in local price. Volume declines were primarily due to impact of the COVID-19 pandemic on the automotive industry and the other key industrial markets.
Operating EBITDA was $599 million for the nine months ended September 30, 2020, down 42 percent compared with pro forma Operating EBITDA of $1,036 million for the nine months ended September 30, 2019 driven primarily by volume declines due to the COVID-19 pandemic, price declines, and approximately $160 million in charges associated with temporarily idling several manufacturing plants to align supply with demand.
SAFETY & CONSTRUCTION
The Safety & Construction segment is a leading provider of engineered products and integrated systems for a number of industries including worker safety, water purification and separation, aerospace, energy, medical packaging and building materials. The segment satisfies the growing global needs of businesses, governments, and consumers for solutions that make life safer, healthier, and better. By uniting market-driven science with the strength of highly regarded brands, the segment strives to bring new products and solutions to solve customers' needs faster, better and more cost effectively.
In millions
| Safety & Construction | Three Months Ended September 30, 2020 | September 30, 2019 | Nine Months Ended September 30, 2020 | September 30, 2019 |
|---|---|---|---|---|
| Net sales | $1,249 | $1,327 | $3,769 | $3,951 |
| Operating EBITDA 1 | $324 | $352 | $1,041 | $1,108 |
| Equity earnings | $7 | $7 | $19 | $22 |
1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis.
| Safety & Construction Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended September 30, 2020 | Nine Months Ended September 30, 2020 |
|---|---|---|
| Local price & product mix | 1% | 2% |
| Currency | — | (1) |
| Volume | (10) | (8) |
| Portfolio & other | 3 | 2 |
| Total | (6)% | (5)% |
Safety & Construction net sales were $1,249 million for the three months ended September 30, 2020, down from $1,327 million for the three months ended September 30, 2019 as a 3 percent increase in portfolio and a 1 percent increase in local price were more than offset by a 10 percent decline in volume. The portfolio impact reflects the recent acquisitions in the Water Solutions business. Local price increased led by Safety Solutions. Volume gains in Water Solutions and demand for TYVEK® protective garments were more than offset by volume declines in Safety and Shelter Solutions due to weakened demand across end markets and declined commercial construction activity as a result of the COVID-19 pandemic.
Operating EBITDA was $324 million for the three months ended September 30, 2020, down 8 percent compared with $352 million for the three months ended September 30, 2019 due to lower volumes and costs associated with capacity reductions to align supply with demand more than offsetting productivity actions and lower raw material costs.
Safety & Construction net sales were $3,769 million for the nine months ended September 30, 2020, down from $3,951 million for the nine months ended September 30, 2019 as a 2 percent increase in local price and 2 percent increase in portfolio were more than offset by a 8 percent volume decline and a 1 percent unfavorable impact from currency. The portfolio impact reflects the recent acquisitions in the Water Solutions business. Volume growth in the segment was led by gains in Water Solutions and TYVEK® protective garment sales within Safety Solutions which were more than offset by weakened demand in end markets for NOMEX® and KEVLAR®. Shelter Solutions volume declined due to the COVID-19 pandemic and the resulting impact on commercial construction activity.
Operating EBITDA was $1,041 million for the nine months ended September 30, 2020, down 6 percent compared with pro forma Operating EBITDA of $1,108 million for the nine months ended September 30, 2019 due to lower volumes, the absence of licensing income, and costs associated with capacity reductions more than offsetting pricing gains, improved product mix, and productivity actions.
NON-CORE
The Non-Core segment is a leading global supplier of key materials for the manufacturing of photovoltaic cells and panels, including innovative metallization pastes, backsheet materials and silicone encapsulants and adhesives. The segment also includes the Company's share of the results of the HSC Group, a U.S.-based group of companies that manufacture and sell polycrystalline silicon products for the photovoltaic and semiconductor industries. Additionally, the segment provides materials used in components and films for consumer electronics, automotive, and aerospace markets. The segment also provides sustainable materials and services for sulfuric acid production and regeneration technologies, alkylation technology for production of clean, high-octane gasoline, and a comprehensive suite of aftermarket service and solutions offerings, including safety consulting and services, to improve the safety, productivity, and sustainability of organizations across a range of industries. The Non-Core segment is also a leading producer of specialty biotechnology materials for carpet and apparel markets as well as polyester films for the healthcare, photovoltaics, electronics, packaging and labels, and electrical insulation industries.
In millions
| Non-Core | Three Months Ended September 30, 2020 | September 30, 2019 | Nine Months Ended September 30, 2020 | September 30, 2019 |
|---|---|---|---|---|
| Net sales | $331 | $431 | $1,005 | $1,327 |
| Operating EBITDA 1 | $14 | $94 | $149 | $296 |
| Equity earnings 2 | $13 | $26 | $121 | $92 |
1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis.
2. Represents equity in earnings (losses) of nonconsolidated affiliates included in pro forma Operating EBITDA, the Company's measure of profit/loss for segment reporting purposes, which excludes significant items. Accordingly, the Non-Core segment presented above excludes a restructuring charge of $1 million and $3 million for the three and nine months ended September 30, 2019 which is presented in "Equity in earnings of nonconsolidated affiliates" in the Company's interim Consolidated Statements of Operations.
| Non-Core Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended September 30, 2020 | Nine Months Ended September 30, 2020 |
|---|---|---|
| Local price & product mix | 5% | 3% |
| Currency | — | (1) |
| Volume | (18) | (17) |
| Portfolio & other | (10) | (9) |
| Total | (23)% | (24)% |
Non-Core net sales were $331 million for the three months ended September 30, 2020, down from $431 million for the three months ended September 30, 2019 due to 5 percent pricing gains more than offset by a 18 percent volume decline and a 10 percent portfolio decline. The portfolio decline was driven by the third quarter 2020 sale of the trichlorosilane ("TCS") business within Photovoltaic & Advanced Materials and the third quarter 2019 sale of the Sustainable Solutions business. Price gains were driven by increased metal prices. Volume gains for photovoltaic materials were more than offset by declines in demand for trichlorosilane, lower volumes in Clean Technologies, and declines in demand for biomaterials as a result of weakened demand in carpet and apparel markets.
Operating EBITDA was $14 million for the three months ended September 30, 2020, down 85 percent compared with $94 million for the three months ended September 30, 2019 due to volume declines, the absence of the gain on the sale of the Sustainable Solutions business, and the absence of earnings from the Sustainable Solutions, TCS, and HSC businesses.
Non-Core net sales were $1,005 million for the nine months ended September 30, 2020, down from $1,327 million for the nine months ended September 30, 2019. Net sales declined due to a 17 percent decline in volume, a 9 percent portfolio decline due to the sale of the Sustainable Solutions and TCS businesses and a 1 percent unfavorable impact from currency, which more than offset a 3 percent increase in local price. Volume declines were driven by declines in demand for trichlorosilane, TEDLAR® aircraft films, biomaterials due to weakened demand in carpet and apparel markets, and lower volumes in Clean Technologies.
Operating EBITDA was $149 million for the nine months ended September 30, 2020, down 50 percent compared with pro forma Operating EBITDA of $296 million for the nine months ended September 30, 2019 as a customer settlement gain of $64 million was more than offset by volume declines, the absence of the gain on the sale of the Sustainable Solutions business, and the absence of earnings from the Sustainable Solutions, TCS, and HSC businesses.
CHANGES IN FINANCIAL CONDITION
Liquidity & Capital Resources
Information related to the Company's liquidity and capital resources can be found in the Company's 2019 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Liquidity and Capital Resources. Discussion below provides the updates to this information for the nine months ended September 30, 2020.
The Company continually reviews its sources of liquidity and debt portfolio and may make adjustments to one or both to ensure adequate liquidity and increase the Company’s optionality and financing efficiency as it relates to financing cost and balancing terms/maturities. The Company’s primary source of incremental liquidity is cash flows from operating activities. COVID-19 continues to adversely impact the broader global economy, including negatively impacting economic growth and creating disruption and volatility in the global financial and capital markets, which could result in increases in the cost of capital and/or adversely impact the availability of and access to capital, which could negatively affect DuPont’s liquidity. Management expects the generation of cash from operations and the ability to access the debt capital markets and other sources of liquidity will continue to provide sufficient liquidity and financial flexibility to meet the Company’s and its subsidiaries obligations as they come due; however, DuPont is unable to predict the extent of COVID-19 related impacts which depends on highly uncertain and unpredictable future developments, including the duration and spread of the COVID-19 outbreak, and the speed and extent of the resumption of normal economic and operating conditions. In light of this uncertainty, the Company has taken steps to further ensure liquidity and capital resources, as discussed below.
In millions
| September 30, 2020 | December 31, 2019 | |
|---|---|---|
| Cash and cash equivalents 1 | $4,008 | $1,540 |
| Total debt | $24,196 | $17,447 |
1. The net proceeds of approximately $6.2 billion from the N&B Notes Offering were recorded within non-current “Restricted cash” in the interim Condensed Consolidated Balance Sheets at September 30, 2020 and thus are not included in "Cash and cash equivalents" as presented in the table above.
The Company's cash and cash equivalents at September 30, 2020 and December 31, 2019 were $4.0 billion and $1.5 billion, respectively, of which $1.7 billion at September 30, 2020 and $1.4 billion at December 31, 2019 were held by subsidiaries in foreign countries, including United States territories. For each of its foreign subsidiaries, the Company makes an assertion regarding the amount of earnings intended for permanent reinvestment, with the balance available to be repatriated to the United States. The increase in cash and cash equivalents was primarily due to receipt of proceeds from the May Debt Offering, discussed further below.
Total debt at September 30, 2020 and December 31, 2019 was $24.2 billion and $17.4 billion, respectively. The increase was primarily due to the N&B Notes Offering and the May Debt Offering, partially offset by a decline in commercial paper.
Term Loan and Revolving Credit Facilities
In November 2018, the Company entered into a term loan agreement that establishes two term loan facilities in the aggregate principal amount of $3 billion, (the “Term Loan Facilities”) as well as a five-year $3 billion revolving credit facility (the “Five-Year Revolving Credit Facility”). Effective May 2, 2019, the Company fully drew the two Term Loan Facilities in the aggregate principal amount of $3 billion and the Five-Year Revolving Credit Facility became effective and available. The Five-Year Revolving Credit Facility is generally expected to remain undrawn, and serve as a backstop to the Company’s commercial paper and letter of credit issuance. In June 2019, the Company entered into a 364-day $750 million revolving credit facility (the “Old 364-Day Revolving Credit Facility”).
In April 2020, the Company entered into a $1.0 billion 364-day revolving credit facility (the “$1B Revolving Credit Facility"). The $1B Revolving Credit Facility replaced the Old 364-Day Revolving Credit Facility, improving the Company’s liquidity position in response to near term uncertainties. As of the effectiveness of the $1B Revolving Credit Facility, the Old 364-Day Revolving Credit Facility was terminated. The $1B Revolving Credit facility may be used for general corporate purposes.
May Debt Offering
On May 1, 2020, the Company completed an underwritten public offering of senior unsecured notes (the “Notes”) in the aggregate principal amount of $2 billion of 2.169 percent fixed rate Notes due May 1, 2023 (the “May Debt Offering”). The proceeds from the May Debt Offering are expected to be used by the Company to repay or redeem the Company’s $0.5 billion in floating rate notes due November 2020 and $1.5 billion of 3.77 percent fixed-rate notes due November 2020 (collectively, the “2020 Notes”). Upon consummation of the Intended N&B Transaction, the Company will be required to mail a notice of redemption to holders of the Notes, with a copy to the Trustee, setting forth the date of redemption of all of the Notes on the date (“Special Mandatory Redemption Date”) that is the later of (i) three (3) Business Days after the consummation of the Intended N&B Transaction and (ii) May 1, 2021. On the Special Mandatory Redemption Date, the Company will be required to redeem all of the Notes at a redemption price equal to 100% of the aggregate principal amount of the Notes plus accrued and unpaid interest, if any, up to but excluding the Special Mandatory Redemption Date. In the event a special mandatory redemption is triggered, the Company expects to fund the redemption with proceeds from the Special Cash Payment.
Commercial Paper
In April 2019, DuPont authorized a $3 billion commercial paper program (the “DuPont Commercial Paper Program”). At September 30, 2020, the Company had issued $390 million of commercial paper ($1.8 billion at December 31, 2019).
Nutrition & Biosciences Financing
In connection with the Intended N&B Transaction, N&B Inc. entered into a Bridge Commitment Letter (the "Bridge Letter") in an aggregate principal amount of $7.5 billion, (the “Bridge Loans”) to secure committed financing for the Special Cash Payment and related financing fees and expenses. The aggregate commitment under the Bridge Letter is reduced by, among other things, (1) the amount of net cash proceeds received by N&B Inc. from any issuance of senior unsecured notes pursuant to a Rule 144A offering or other private placement and (2) certain qualifying term loan commitments under senior unsecured term loan facilities.
In January 2020, N&B Inc. entered into a senior unsecured term loan agreement in the amount of $1.25 billion split evenly between three- and five-year facilities (the "N&B Term Loan Facilities"). As a result of entry into the term loan agreement, the commitments under the Bridge Commitment Letter were reduced to $6.25 billion.
On September 16, 2020 (the “Offering Date”), N&B Inc. completed an offering in the aggregate principal amount of $6.25 billion of senior unsecured notes in six series, comprised of the following (collectively, the “N&B Notes Offering" and together with the N&B Term Loan Facilities, the “Permanent Financing”): $300 million aggregate principal amount of 0.697% Senior Notes due 2022; $1.0 billion aggregate principal amount of 1.230% Senior Notes due 2025; $1.2 billion aggregate principal amount of 1.832% Senior Notes due 2027; $1.5 billion aggregate principal amount of 2.300% Senior Notes due 2030; $750 million aggregate principal amount of 3.268% Senior Notes due 2040; and $1.5 billion aggregate principal amount of 3.468% Senior Notes due 2050. As a result of the N&B Notes Offering, the commitments under the Bridge Commitment Letter were further reduced to zero and terminated on and as of the Offering Date.
The net proceeds of approximately $6.2 billion from the N&B Notes Offering were deposited into an escrow account. The release of the net proceeds from the N&B Notes Offering and the availability of funding under the term loan agreement are subject to customary closing conditions including among others, the satisfaction of substantially all the conditions to the consummation of the intended transaction with IFF. The proceeds from the Permanent Financing will be used to make the Special Cash Payment and to pay the related financing fees and expenses. The obligations and liabilities associated with the Permanent Financing will be separated from the Company upon consummation of the Intended N&B Transaction. However, if the closing of the Intended Merger has not occurred on or prior to September 15, 2021, or, if prior to such date, the Merger Agreement is validly terminated, (each a “Special Mandatory Redemption Event”), N&B Inc. must redeem all of the Notes on or before the 15th business day following the Special Mandatory Redemption Event (such date of redemption, the “Special Mandatory Redemption Date”) at a redemption price equal to 101% of the aggregate principal amount of the applicable series of Notes, plus accrued and unpaid interest to, but not including, the Special Mandatory Redemption Date. Borrowing under the term loan agreement would occur immediately prior to the closing of the Intended N&B Transaction.
Pursuant to the Merger Agreement, the fees and expenses associated with the financing will be borne (A) entirely by N&B Inc. if the transaction closes; and (B) equally by DuPont and IFF if the Merger Agreement terminates. However, if the Merger Agreement is terminated by IFF, in accordance with its terms, for breach by DuPont, such fees and expenses will be borne entirely by DuPont; and if terminated by DuPont in accordance with its terms for breach by IFF, such fees and expenses will be borne entirely by IFF.
Credit Ratings
The Company's credit ratings impact its access to the debt capital markets and cost of capital. The Company remains committed to a strong financial position and strong investment-grade rating. At October 28, 2020, DuPont's credit ratings were as follows:
| Credit Ratings | Long-Term Rating | Short-Term Rating | Outlook |
| Standard & Poor’s | BBB+ | A-2 | Negative Watch |
| Moody’s Investors Service | Baa1 | P-2 | Stable |
| Fitch Ratings | BBB+ | F-2 | Stable |
The Company's indenture covenants related to its 2018 Senior Notes and May Debt Offering contains certain limitations on the Company’s ability to incur liens and enter into sale lease-back transactions, mergers and consolidations as well as customary events of default. The Term Loan Facilities, the Five-Year Revolving Credit Facility and the $1B Revolving Credit Facility contain a financial covenant, typical for companies with similar credit ratings, requiring that the ratio of Total Indebtedness to Total Capitalization for the Company and its consolidated subsidiaries not exceed 0.60. At September 30, 2020, the Company was in compliance with this financial covenant.
Summary of Cash Flows
The Company’s cash flows from operating, investing and financing activities, as reflected in the interim Consolidated Statements of Cash Flows, are summarized in the following table. The cash flows related to the Materials Science and Agriculture businesses have not been segregated and are included in the interim Consolidated Statements of Cash Flows for the nine months ended September 30, 2019.
In millions
| Cash Flow Summary Cash provided by (used for): | Nine Months Ended September 30, 2020 | 2019 |
|---|---|---|
| Operating activities | $2,794 | $831 |
| Investing activities | $35 | $(1,807) |
| Financing activities | $5,830 | $(10,897) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $4 | $(2) |
Cash Flows from Operating Activities
In the first nine months of 2020, cash provided by operating activities was $2,794 million, compared with $831 million in the same period last year. The increase in cash provided by operating activities was primarily due to a decrease in cash used for working capital, offset by the impact of the DWDP Distributions to period earnings.
| Net Working Capital In millions (except ratio) | Sept 30, 2020 | Dec 31, 2019 |
|---|---|---|
| Current assets | $12,606 | $9,999 |
| Current liabilities | 6,984 | 8,346 |
| Net working capital | $5,622 | $1,653 |
| Current ratio | 1.80:1 | 1.20:1 |
Cash Flows from Investing Activities
In the first nine months of 2020, cash provided by investing activities was $35 million, compared with cash used for investing activities of $1,807 million in the first nine months of 2019. Cash provided by investing activities was driven by proceeds from sales of property and businesses in 2020 and lower capital expenditures compared to the same period of prior year. The first nine months of 2019 also contains activity related to the Materials Science and Agriculture businesses prior to the DWDP Distributions.
Cash Flows from Financing Activities
In the first nine months of 2020, cash provided by financing activities was $5,830 million compared with cash used for financing activities of $10,897 million in the same period last year. The primary driver of the increase in cash provided was an increase in proceeds from issuances of long-term debt as well as a decrease in cash used for payments related to the DWDP Distributions of the Materials Science and Agriculture businesses, a reduction in payments on long-term debt, and a reduction in share repurchase of common stock, partially offset by decreased issuances of short-term notes payable. The first nine months of 2019 also contains activity related to the Materials Science and Agriculture businesses prior to the DWDP Distributions.
Dividends
On February 12, 2020, the Board of Directors declared a first quarter dividend of $0.30 per share, paid on March 16, 2020, to shareholders of record on February 28, 2020.
On April 29, 2020, the Company announced that its Board declared a second quarter dividend of $0.30 per share, paid on June 15, 2020, to shareholders of record on May 29, 2020.
On June 25, 2020, the Company announced that its Board declared a third quarter dividend of $0.30 per share paid on September 15, 2020, to shareholders of record on July 31, 2020.
On October 14, 2020, the Company announced that its Board of Directors declared a fourth quarter dividend of $0.30 per share payable on December 15, 2020, to shareholders of record on November 30, 2020.
Share Buyback Programs
On June 1, 2019, the Company's Board of Directors authorized a new $2 billion share buyback program, which expires on June 1, 2021. During the third quarter of 2020, the Company did not repurchase any shares. As of September 30, 2020, the Company repurchased 16.9 million shares under this program since inception at a total cost of $982 million. See Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds, for additional information.
Pension and Other Post-Employment Plans
DuPont expects to make additional contributions in the aggregate of approximately $30 million by year-end 2020 to certain non-US pension and other post-employment benefit plans. Any such contribution could be funded by existing cash balances and/or cash from other available sources of liquidity.
Restructuring
In March 2020, the Company approved restructuring actions designed to capture near-term cost reductions following the expected closure of the Intended N&B Transaction (the "2020 Restructuring Program"). As a result of these actions, the Company recorded pre-tax restructuring charges of $140 million inception-to-date, consisting of severance and related benefit costs of $112 million and asset related charges of $28 million. The Company expects actions related to this program to be substantially complete by the end of 2020. Future cash payments related to the 2020 Restructuring Program are anticipated to be $70 million primarily related to the payment of severance and related benefits.
In June 2019, DuPont approved restructuring actions to simplify and optimize certain organizational structures following the completion of the DWDP Distributions (the "2019 Restructuring Program"). As a result of these actions, the Company has recorded pre-tax restructuring charges of $140 million inception-to-date, consisting of severance and related benefit costs of $106 million and asset related charges of $34 million. Actions associated with the 2019 Restructuring Program are considered substantially complete. Future cash payments related to the 2019 Restructuring Program are anticipated to be $27 million, primarily related to the payment of severance and related benefits.
In September and November 2017, the Company approved post-merger restructuring actions under the DowDuPont Cost Synergy Program, adopted by the DowDuPont Board of Directors. The DowDuPont Cost Synergy Program was designed to integrate and optimize the organization following the DWDP Merger and in preparation for the DWDP Distributions whereby the Company has recorded pre-tax restructuring charges attributable to the continuing operations of DuPont of $489 million inception-to-date, consisting of severance and related benefit costs of $213 million, asset related charges of $209 million and contract termination charges of $67 million. The activities related to the DowDuPont Cost Synergy Program are expected to result in additional cash expenditures of $30 million consisting of severance and related benefit costs and contract terminations. Actions associated with the DowDuPont Cost Synergy Program, including employee separations, are considered substantially complete (see Note 5 to the interim Consolidated Financial Statements).
Off-balance Sheet Arrangements
Guarantees arise in the ordinary course of business from relationships with customers and nonconsolidated affiliates when the Company undertakes an obligation to guarantee the performance of others if specific triggering events occur. At September 30, 2020 and December 31, 2019, the Company had directly guaranteed $177 million and $187 million, respectively, of such obligations. Additional information related to the guarantees of the Subsidiaries can be found in the “Guarantees” section of Note 13 to the interim Consolidated Financial Statements.
Contractual Obligations
Information related to the Company's contractual obligations at December 31, 2019 can be found in the Company's 2019 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Contractual Obligations. There were no material changes to the Company's contractual obligations during the first nine months of 2020, outside of the items shown below.
In millions
| Total at September 30, 2020 | Payments Due In Remainder of 2020 | 2021-2022 | 2023-2024 | 2025 and beyond | |
|---|---|---|---|---|---|
| Long-term debt obligations 1 | $23,959 | $2,001 | $3,307 | $4,801 | $13,850 |
| Expected cash requirements for interest 1 | 9,546 | 311 | 1,463 | 1,209 | 6,563 |
| Total contractual obligations | $33,505 | $2,312 | $4,770 | $6,010 | $20,413 |
1. A portion of these obligations relate to the N&B Notes Offering. The obligations associated with the N&B Notes Offering will be separated from the Company upon consummation of the Intended N&B Transaction. Refer to the Liquidity and Capital Resources section for more information.
OTHER MATTERS
Recent Accounting Guidance
See Note 2 to the interim Consolidated Financial Statements for a description of recent accounting guidance.
Critical Accounting Estimates
The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make judgments, assumptions and estimates that affect the amounts reported in the interim Consolidated Financial Statements and accompanying notes. Note 1 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (“2019 Annual Report”) describes the significant accounting policies and methods used in the preparation of the Consolidated Financial Statements. DuPont’s accounting policies that are impacted by judgments, assumptions and estimates are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s 2019 Annual Report. Since December 31, 2019, there have been no material changes in the Company’s accounting policies that are impacted by judgments, assumptions and estimates. See the discussion in this section for information regarding the valuation of assets and impairment considerations.
Valuation of Assets and Impairment Considerations
The Company tests goodwill and indefinite-lived intangible assets for impairment annually during the fourth quarter as of October 1, or more frequently when events or changes in circumstances indicate that the fair value is below its carrying value. Goodwill is evaluated for impairment using qualitative and/or quantitative testing procedures. The Company performs goodwill impairment testing at the reporting unit level which is defined as the operating segment or one level below the operating segment. One level below the operating segment, or component, is a business in which discrete financial information is available and regularly reviewed by segment management. The Company aggregates certain components into reporting units based on economic similarities.
As a result of the related acquisition method of accounting in connection with the DWDP Merger, Historical EID’s assets and liabilities were measured at fair value resulting in increases to the Company’s goodwill and other intangible assets. The fair value valuation increased the risk that declines in financial projections, including changes to key assumptions, could have a material, negative impact on the fair value of the Company’s reporting units and assets, and therefore could result in an impairment.
COVID-19 continues to adversely impact the broader global economy and has caused significant volatility in financial markets. If there is a of lack of recovery, the time period to recovery is longer than expected or further global softening is experienced in certain markets, such as automotive, aerospace, commercial construction, oil & gas and select industrial end-markets, or a sustained decline in the value of the Company's common stock, the Company may be required to perform additional impairment assessments for its goodwill, other intangibles, and long-lived assets, the results of which could result in material impairment charges.
Market risk
As filed, 324 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
See Note 19 to the interim Consolidated Financial Statements. See also Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of the Company's 2019 Annual Report on Form 10-K for information on the Company's utilization of financial instruments and an analysis of the sensitivity of these instruments.
Controls and procedures
As filed, 1,908 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
The Company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the Company's reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.
As of September 30, 2020, the Company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO), together with management, conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.
Changes in Internal Control Over Financial Reporting
There were no changes in the Company's internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15 that was conducted during the three months ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
In connection with the Intended N&B Transaction, there are several processes, policies, operations, technologies and information systems that are expected to be transferred or separated. During the quarter ended September 30, 2020, the Company continues to take steps to ensure that adequate controls are designed and maintained throughout this transition period.
DuPont de Nemours Inc. PART II - OTHER INFORMATION
Risk factors
As filed, 3,737 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Other than the risk factor set forth below, there have been no material changes in the Company's risk factors discussed in Part I, Item 1A, Risk Factors, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
The extent to which the novel coronavirus (COVID-19) and measures taken in response to it, impact DuPont’s business, results of operations, access to sources of liquidity and financial condition depends on future developments, which are highly uncertain and cannot be predicted.
DuPont is actively monitoring the global impacts of COVID-19, including the impacts from responsive measures, and remains focused on its top priorities - the safety and health of its employees and the needs of its customers. The Company’s business and financial condition, and the business and financial condition of the company’s customers and suppliers, have been impacted by the significantly increased economic and demand uncertainties created by the COVID-19 outbreak. In addition, public and private sector responsive measures, such as the imposition of travel restrictions, quarantines, adoption of remote working, and suspension of non-essential business and government services, have impacted the company’s business and financial condition. Many of DuPont’s facilities and employees are based in areas impacted by the virus. While most DuPont manufacturing sites remain in operation, DuPont has reduced or furloughed certain operations in response to government measures, employee welfare concerns and the impact of COVID-19 on the global demand and supply chain. DuPont’s manufacturing operations may be further adversely affected by impacts from COVID-19 including, among other things, additional government actions and other responsive measures, more and /or deeper supply chain disruptions, quarantines and health and availability of essential onsite personnel. Furthermore, COVID-19 continues to adversely impact the broader global economy, including negatively impacting economic growth and creating disruption and volatility in the global financial and capital markets, which could result in increases in the cost of capital and/or adversely impact the availability of and access to capital, which could negatively affect DuPont’s liquidity. DuPont is unable to predict the extent of COVID-19 related impacts on its business, results of operations, access to sources of liquidity and financial condition which depends on highly uncertain and unpredictable future developments, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume. DuPont’s financial results may be materially and adversely impacted by a variety of factors that have not yet been determined, including potential impairments of goodwill and other assets. DuPont is taking actions, including reducing costs, restructuring actions, and delaying certain capital expenditures and non-essential spend. In addition, the Company may consider further reductions in or furloughing additional operations in response to further and/or deeper declines in demand and/or or supply chain disruptions. There can be no guaranty that such actions will significantly mitigate the impact of COVID-19 on the company’s business, results of operations, access to sources of liquidity or financial condition. After the COVID-19 outbreak has subsided, DuPont may experience materially adverse impacts to its business, results of operations and financial condition as a result of related global economic impacts, including any recession that has occurred or may occur in the future.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2020-07-01 to 2020-09-30 | $3.39bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2020-01-01 to 2020-09-30 | $10.00bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2020-07-01 to 2020-09-30 | $199.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $644.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2020-07-01 to 2020-09-30 | $524.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2020-01-01 to 2020-09-30 | $1.70bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Income tax | 3 months2020-07-01 to 2020-09-30 | $92.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $100.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | −$79.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | −$3.17bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | −$4.31 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-07-01 to 2020-09-30 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-01-01 to 2020-09-30 | −$4.31 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-07-01 to 2020-09-30 | 734,400,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-01-01 to 2020-09-30 | 735,800,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Cash and equivalents | At period end2020-09-30 | $4.01bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $12.61bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $72.14bn | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $6.98bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $34.02bn | us-gaap:Liabilities |
| Long-term debt | At period end2020-09-30 | −$23.81bn | us-gaap:LongTermDebt |
| Current portion of debt | At period end2020-09-30 | $2.39bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2020-09-30 | $37.56bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001666700-20-000053. Last ingested by Listed: Nov 10, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.